Informações:
Falhas:
ID
38648
Descrição
A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril; ODM derived from: https://clinicaltrials.gov/show/NCT01398267
Link
https://clinicaltrials.gov/show/NCT01398267
Palavras-chave
Versões (1)
- 29/10/2019 29/10/2019 -
Titular dos direitos
See clinicaltrials.gov
Transferido a
29 de outubro de 2019
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Diabetes Mellitus, Type 2 NCT01398267
Eligibility Diabetes Mellitus, Type 2 NCT01398267
- StudyEvent: Eligibility
Similar models
Eligibility Diabetes Mellitus, Type 2 NCT01398267
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Adult | Age
Item
adult male and female patients, 18 to 65 years of age, inclusive
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0001779 (UMLS CUI [2])
Non-Insulin-Dependent Diabetes Mellitus Disease length
Item
diabetes mellitus type 2, diagnosed at least 3 months before screening
boolean
C0011860 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
C0872146 (UMLS CUI [1,2])
Metformin Dose Stable
Item
treated with stable dose of metformin for at least 4 weeks prior to screening
boolean
C0025598 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
C0178602 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
Angiotensin-Converting Enzyme Inhibitors Dose Stable
Item
treated with stable dose of angiotensin-converting enzyme inhibitor (acei) for at least 4 weeks prior to screening
boolean
C0003015 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
C0178602 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
Body mass index
Item
body mass index (bmi) 18 to 38 kg/m2, inclusive
boolean
C1305855 (UMLS CUI [1])
HIV-1 infection | HIV-2 infection | Hepatitis B | Hepatitis C
Item
positive for hiv-1, hiv-2, hepatitis b or hepatitis c infection
boolean
C2363741 (UMLS CUI [1])
C0854094 (UMLS CUI [2])
C0019163 (UMLS CUI [3])
C0019196 (UMLS CUI [4])
C0854094 (UMLS CUI [2])
C0019163 (UMLS CUI [3])
C0019196 (UMLS CUI [4])
Pregnancy | Breast Feeding
Item
pregnant or lactating females
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])
Diabetes Mellitus, Insulin-Dependent | Secondary diabetes mellitus
Item
type 1 diabetes or secondary from of diabetes
boolean
C0011854 (UMLS CUI [1])
C0271640 (UMLS CUI [2])
C0271640 (UMLS CUI [2])
Proliferative diabetic retinopathy | Neuropathy
Item
history or evidence of proliferative diabetic retinopathy or clinically significant neuropathy
boolean
C0154830 (UMLS CUI [1])
C0442874 (UMLS CUI [2])
C0442874 (UMLS CUI [2])
Liver disease
Item
clinically significant hepatic disease
boolean
C0023895 (UMLS CUI [1])
Renal Insufficiency
Item
clinically significant renal impairment
boolean
C1565489 (UMLS CUI [1])
Cardiovascular Disease
Item
history or evidence of clinically significant cardio-vascular disease or disorder
boolean
C0007222 (UMLS CUI [1])
Communicable Disease Treatment required for | Malignant Neoplasms Treatment required for | Exception Excision Basal cell carcinoma
Item
acute infection or current malignancy requiring treatment except for excised basal cell carcinoma
boolean
C0009450 (UMLS CUI [1,1])
C0332121 (UMLS CUI [1,2])
C0006826 (UMLS CUI [2,1])
C0332121 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0728940 (UMLS CUI [3,2])
C0007117 (UMLS CUI [3,3])
C0332121 (UMLS CUI [1,2])
C0006826 (UMLS CUI [2,1])
C0332121 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0728940 (UMLS CUI [3,2])
C0007117 (UMLS CUI [3,3])